Emily has founded five biotech start-ups, addressing challenges in fields including the sympathetic nervous system, infectious disease diagnostics, exosome biology and cancer diagnostics, pulmonary fibrosis, and periodontal disease, and is a respected authority in the realm of oral microbiome and soft tissue inflammation. The microbiome modulatory technology that she has developed holds promise in addressing an array of diseases that range from dental cavities and periodontal disease to cancer and diabetes.